InnoModels Biotechnology has always been committed to driving innovation in the field of cancer treatment and leading the way in immunotherapy. The company's latest immune co-culture killing model is not only a technological breakthrough, but also provides researchers with an experimental platform that is closer to the physiological context in vivo, which helps to understand the mechanism of immune cell-tumor cell interactions, and provides critical support for the development of personalized treatment plans.
Features of the model
1. 3D tissue simulation:
The new immune co-culture killing model constructs a more realistic three-dimensional tissue structure through precise cell culture technology, simulating the complex interactions between immune cells and tumour cells in vivo. This helps to more accurately predict the effects of therapeutic drugs in vivo.
2. Participation of multiple cell types:
Different from the traditional immune model, the model can simultaneously introduce multiple immune cell types, such as natural killer cells (NK cells), T cells, etc., to simulate a more complex immune response process, so that the experimental results are more biologically meaningful.
3. Visualisation technology support:
Using advanced microscopy techniques and imaging analysis, our model is able to provide real-time observation at the cellular level. This visualisation feature enables researchers to intuitively observe the killing process of immune cells, which helps to gain a deeper understanding of the mechanisms of immunotherapy.
4. Biomarker analysis:
The model allows for exhaustive analysis of biomarkers in the immune response, helping researchers to identify potential predictive indicators that provide an important basis for clinical research and the design of therapeutic regimens.

Application Areas
The new immune co-culture killing model has a wide range of applications in cancer therapeutic research, including but not limited to:
Drug screening and evaluation:
Efficiently and accurately assess the immunocidal effect of potential therapeutic drugs.
Mechanistic studies:
In-depth study of the immune response mechanisms involved in different immune cells, revealing the complex interactions between therapeutic drugs and the immune system.
Immune cell engineering:
Optimise the engineering of immune cells to improve their ability to recognise and kill tumour cells.
Personalised therapy:
Tailor the treatment plan based on the immune profile of the patient to improve the individualisation of the treatment.
Conclusion
The launch of the immune co-culture killing model by InnoModels Biotechnology marks an important leap forward in immunotherapy research. We believe that through the widespread application of this model, it will provide a deeper understanding of the future of cancer treatment and a solid scientific foundation for researchers and physicians to develop more effective treatment protocols. InnoModels Biotechnology will continue its efforts to promote innovation in the field of immunotherapy, bringing more hope and possibilities to patients.